Lexicon rises on new Phase II diabetes data; still no partner
This article was originally published in Scrip
Executive Summary
Lexicon Pharmaceuticals doesn't have a partner to advance its dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) into Phase III clinical trials, but the company's stock still gained 21.4% to close at $2.89 per share on 1 October based on statistically significant top-line results from a small Phase II trial for the oral diabetes drug LX4211.